Trials / Completed
CompletedNCT01275209
Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma
A Phase Ib, Multicenter, Open-label Study of HCD122 Administered Intravenously in Combination With Bendamustine in Patients With CD40+ Follicular Lymphoma Who Are Refractory to Rituximab
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety and efficacy of HCD122 (Lucatumumab) when combined with bendamustine in patients with follicular lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HCD122 |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2012-05-01
- Completion
- 2012-05-01
- First posted
- 2011-01-12
- Last updated
- 2020-12-08
Locations
12 sites across 7 countries: United States, Australia, Belgium, Canada, France, Italy, Spain
Source: ClinicalTrials.gov record NCT01275209. Inclusion in this directory is not an endorsement.